The US AI research company Anthropic has become known for building powerful AI models while simultaneously warning about ...

Assail, the pioneer in autonomous red teaming powered by recursive self-improvement AI, today announced Sidewindertm, a ...

In late June 2026, Recursion Pharmaceuticals, Inc. was added to multiple Russell value and small-cap benchmarks, including ...

Under the combination, first announced in August, Exscientia will become a wholly-owned subsidiary of Recursion, creating a trans-Atlantic AI powerhouse with a pipeline of more than 10 clinical and ...

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

The Council for the Indian School Certificate Examinations (CISCE) has released the ISC Computer Science (Subject Code - 868) for the Year 2027 evaluation cycle. It is designed specifically to make ...

Recursive self-improvement AI now has a co-evolving evaluator: a Cambridge and NVIDIA preprint introduces the Red Queen Gödel ...

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new investment opportunities through TipRanks' ...

As AI moves from experimentation to business-critical operations, leadership teams will need to look beyond pilot outcomes and technical performance.

Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive early clinical data from its AI driven drug discovery programs. The company highlighted progress in oncology and rare disease candidates in ...

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...